—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Alnylam Pharmaceuticals Inc (ALNY) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ALNY, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.79 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How ALNY has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.79 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Alnylam Pharmaceuticals Inc moved 0.79% on average · correlation 0.16 · higher than 76% of US names
  • Beta, last 3 months 1.48 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.57% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.25% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against ALNY on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Alnylam Pharmaceuticals Inc

ALNY in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Alnylam develops medicines built on RNA interference, a method that silences disease-causing genes rather than targeting the proteins they make. It sells treatments for hereditary amyloidosis, high cholesterol, haemophilia, acute porphyria and a rare kidney disorder, and runs a pipeline of experimental drugs through several trial phases. It partners with larger drugmakers such as Regeneron, Roche, Sanofi and Novartis to develop and market some of these medicines. It is based in Cambridge, Massachusetts.
Where it sits in the stack
Alnylam does not sit in Rubin, the diary's index for the AI build-out; it belongs to the Healthcare sector of our wider universe, in the Biotechnology industry group, alongside drug developers outside the compute stack.
Who it is priced against
Closelooknet's peer group for this name is not set; the comparison the market draws is with Ionis Pharmaceuticals, another company built on gene-silencing chemistry.
Why Closelooknet tracks it
It holds a Nasdaq-100 seat but no Rubin seat and carries no Closelooknet score; the diary has not yet quoted it in its editions.
What the diary watches
Whether the phase 3 readouts for its pipeline compounds turn into approvals, which the diary watches as the path from trial to marketed medicine.

Alnylam Pharmaceuticals Inc (ALNY) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by BMO Capital, 2026-08-18

The Street on this name

Analyst actions and the latest print for ALNY from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target BMO Capital — target 318 Target set to $318 (+39.1% to spot) 2026-08-18

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Alnylam Pharmaceuticals Inc (ALNY)?

Alnylam Pharmaceuticals Inc trades as ALNY on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is ALNY in a Closelooknet index?

Not currently — Alnylam Pharmaceuticals Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does ALNY trade against its moving averages?

Recovery attempt under the 200-day: Trades +4.8% vs the 50-day and -16.6% vs the 200-day average, 48.3% below the 52-week high and +29.4% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Alnylam Pharmaceuticals Inc trade when bond yields rise?

Over the past year Alnylam Pharmaceuticals Inc had a beta of 0.79 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 76% of US names. On the 10 sessions in which long bonds fell most it moved −0.57% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Alnylam Pharmaceuticals Inc do?

Alnylam develops medicines built on RNA interference, a method that silences disease-causing genes rather than targeting the proteins they make. It sells treatments for hereditary amyloidosis, high cholesterol, haemophilia, acute porphyria and a rare kidney disorder, and runs a pipeline of experimental drugs through several trial phases. It partners with larger drugmakers such as Regeneron, Roche, Sanofi and Novartis to develop and market some of these medicines. Closelooknet's peer group for this name is not set; the comparison the market draws is with Ionis Pharmaceuticals, another company built on gene-silencing chemistry.

Where does Alnylam Pharmaceuticals Inc sit in the AI build-out?

Alnylam does not sit in Rubin, the diary's index for the AI build-out; it belongs to the Healthcare sector of our wider universe, in the Biotechnology industry group, alongside drug developers outside the compute stack. It holds a Nasdaq-100 seat but no Rubin seat and carries no Closelooknet score; the diary has not yet quoted it in its editions.

What has Wall Street done on Alnylam Pharmaceuticals Inc recently?

The most recent analyst action on Alnylam Pharmaceuticals Inc on the Closelooknet wire is a price target by BMO Capital on 2026-08-18 (target 318). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ALNY, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.